Olympus Corporation (President: Tsuyoshi Kikukawa) plans to open a new complex, the Mishima Facility, in Sunto-gun, Shizuoka Prefecture, on April 2, 2007. The new facility will be located in Shizuoka' s Pharma Valley-Nagaizumi Industrial Park.

Development, quality assurance and customer support operations for the diagnostic business will be transferred to the new facility, together with the production operations of Mishima Olympus Co., Ltd. (President: Noriaki Takahashi), the manufacturing subsidiary for this segment, and the bone substitute manufacturing operations of Olympus Terumo Biomaterials Corp. (President: Hitoshi Mizuno)*. As a new hub for the Olympus Group' s medical and life science activities, the Mishima Facility is expected to make an important contribution to the advancement of next-generation medical technology.

Olympus is determined that the new facility will set a new standard for environmental soundness. Environmental measures during the construction phase will include noise reduction measures. The buildings and facilities will be designed for optimal environmental efficiency, and there will be continual environmental improvement initiatives after the facility becomes operational. The establishment of the Mishima Facility is the first private sector initiative under Shizuoka' s Pharma Valley concept, the aim of which is to establish a cluster of advanced health industry facilities around the Shizuoka Cancer Center, in an area at the foot of Mount Fuji.

*	Development and quality assurance operations for the diagnostic business and the operations of Mishima Olympus will be transferred from other locations in Nagaizumi-cho, and customer support services from Hachioji City, Tokyo. The bone substitute, "BONECERAM" manufacturing operations of Olympus Terumo Biomaterials will be relocated from Ichikawa City, Chiba Prefecture.

Background to the Establishment of the Mishima Facility

The diagnostic business is one of the core segments for Olympus Corporation' s Life Science Group. With development and production sites in Japan, Germany and Ireland, Olympus is globally active in this field. Within Japan, development, production and quality assurance operations for diagnostic systems are based in Shizuoka Prefecture, while training and other customer support activities are provided from facilities in Hachioji City. By centralizing all of these activities in Mishima, it will be possible to bring development, production and quality assurance operations closer to users so that user input can be reflected directly in newly developed products and services. The relocation of the manufacturing subsidiary will allow the expansion of equipment production lines, resulting in a doubling of capacity.

Olympus Terumo Biomaterials Corp., which was recently renamed Olympus Biomaterial Corp., will commence operations on April 1, 2007. It has acquired the bone substitute business of Sumitomo Osaka Cement Co., Ltd. and will relocate manufacturing facilities for bone replacement materials, which are made primarily from hydroxyapatite, to Mishima, where it will commence its own production operations.

The Mishima Facility has been established as a new organizational unit for these operations, and as a base for the life science activities of the entire Olympus Group. Olympus aims to make the new facility a focus for the development of next-generation medical science.

Setting a New Standard in Environmental Soundness

Olympus has achieved ISO14001 certification for environmental management systems at its plants, not only in Japan, but also at facilities in Europe, North America, China and the Philippines. Its goal is to minimize environmental loads through structured systematic management. The new Mishima Facility is seen as a model for future environmental efforts. In addition to the installation of systems that are highly effective in reducing environmental loads, Olympus also aims to instill a strong sense of environmental awareness in employees at the facility through a sustained and active commitment to environmental improvement activities in the context of day-to-day operations. To reduce energy consumption, the new buildings will feature improved thermal insulation and highly efficient air conditioning systems. In this way, Olympus will contribute to the prevention of global warming, which has been one of the most serious effects of environmental loads in the past. Ongoing environmental activities, including the efficient operation of facilities based on control data and power monitoring data, will be reinforced by environmental education programs for all employees at the Mishima Facility.

1. Environmental Facilities at the Mishima Facility
   
2. Features that will help to prevent global warming
   Control system High-efficiency air-conditioning control system
   High-efficiency systems Upright thermal storage tank (diameter: 5m, height: 25m, capacity: 438m³ ) for recycling of pure water or rainwater)
   Thermal insulation: Low double-glazing to shield the interior from external temperatures, gradation blinds to admit the optimal level of external light, and other innovations
   
3. Harmony with the natural environment
   Garden terrace, solar power (50KwH system to be installed in fiscal 2007)
   

Outline of the Mishima Facility

General Manager	Masao Agawa
Address	454-1 Higashino, Nagaizumi-cho, Sunto-gun, Shizuoka Prefecture
Site area	27,348m2
Total floor area	19,759m2 (Building A: 15,944m2, Building B: 3,815m2)
Buildings	Building A: 4 stories, informally named the Life Scientific Techno-CenterDevelopment, quality assurance and customer support operations for Olympus Corporation' s diagnostic business Mishima Olympus Co., Ltd.
	Building B: 2 stories, informally named the Biomaterials WorksProduction operations for bone replacement materials manufactured by Olympus Terumo Biomaterials
Building structure	Building A and Building B: RCSS (pillars: reinforced concrete, beams: steel-frame)
Employees	Approximately 350